Deoxyribozymes: Cleaving a path to clinical trials

Trends in Pharmacological Sciences

Volumn 25, Issue 8, 2004, Pages 395-397

  Dass, Crispin R ^a  

^a GeneType   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DEOXYRIBOZYME; FOMIVIRSEN; MAGNESIUM; MESSENGER RNA; PROTEIN C JUN; PURINE; PYRIMIDINE; VASCULOTROPIN RECEPTOR 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; APOPTOSIS; ARTERY WALL; BLOOD VESSEL; CANCER; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL LINE; CELL MOTION; CYTOSOL; DOWN REGULATION; DRUG ISOLATION; DRUG TARGETING; ELECTROPORATION; ENDOSOME; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENE SILENCING; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTOXICITY; INFLAMMATION; INTIMA; MACROMOLECULE; MACROPHAGE; MOLECULAR SIZE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PSORIASIS; RNA CLEAVAGE; SHORT SURVEY; T LYMPHOCYTE; TARGET CELL; TUMOR VOLUME; VIRUS RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DNA, CATALYTIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; RNA, MESSENGER;

EID: 3242759845     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.06.001     Document Type: Short Survey

References (16)

1. Haseloff J., Gerlach W. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 334:1988;585-591
2. Sun L.-Q., et al. Catalytic nucleic acids: from lab to applications. Pharmacol. Rev. 52:2000;325-347
3. Dass C.R. Vehicles for oligonucleotide delivery to tumours. J. Pharm. Pharmacol. 54:2002;3-27
4. Santoro S.W., Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U. S. A. 94:1997;4262-4266
5. Cairns M.J., et al. Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol. 17:1999;480-486
6. Dass C.R., et al. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 12:2002;289-299
7. Cieslak M., et al. DNAzymes to β1 and β3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J. Biol. Chem. 277:2002;6779-6787
8. Hjiantoniou E., et al. DNAzyme-mediated cleavage of Twist transcripts and increase in cellular apoptosis. Biochem. Biophys. Res. Commun. 300:2003;178-181
9. Chakraborti S., Banerjea A.C. Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: Potential effectiveness against all HIV-1 isolates. Mol. Ther. 7:2003;817-826
10. Santiago F.S., et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med. 5:1999;1264-1269
11. Lowe H.C., et al. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ. Res. 89:2001;670-677
12. Khachigian L.M., et al. c-Jun regulates vascular vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J. Biol. Chem. 277:2002;22985-22991
13. Lowe H.C., et al. Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thromb. Haemost. 87:2002;134-140
14. Nunamaker E.A., et al. Electroporation-mediated delivery of catalytic oligodeoxynucleotides for manipulation of vascular gene expression. Am. J. Physiol. Heart Circ. Physiol. 285:2003;H2240-H2247
15. Zhang L., et al. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res. 62:2002;5463-5469
16. Fahmy R.G., et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularisation and tumor growth. Nat. Med. 9:2003;1026-1032